Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept long-term safety rollover study
NL-OMON56073Phase 3Recruiting
- Sponsor
- Celgene Corporation
- Start
- Aug 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of luspatercept, sponsored by Celgene Corporation. Started Aug 2020; status: recruiting.
02
Drugs
luspatercept
Beyond the preview
Go deeper on NL-OMON56073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56073.